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Introduction
Patients with asthma have been reported to be at
increased risk of invasive pneumococcal disease (IPD).
Therefore, routine vaccination against Streptococcus
Pneumoniae is suggested for all children suffering from
asthma or recurrent wheeze. Inhaled corticosteroids
(ICS) are the preferred treatment for initiating long-
term control therapy in these children. Their effect on
the immunogenicity of PCV13 is yet unknown.
Aim
To evaluate the immunogenicity of PCV13, in children
with asthma or recurrent wheeze, receiving medium
doses of ICS for extended periods of time.
Method
40 children (26 boys) with asthma or recurrent wheeze
(mean age 4,3 ± 1,05 years) were assigned to 3 groups
according to the duration of their ICS therapy (1st
<30days, 2nd 30-90 days, 3rd >90 days, dosage 200-
250μg/day of inhaled fluticasone in all groups). 13
healthy age-matched children were included in the
study as controls (group 0). All children received for the
first time one dose of PCV13. Pneumococcal serotype
(PS) specific IgG antibodies to serotypes 3 and 19A
were measured by ELISA, before and 31,9 ± 5,6 days
after vaccination. IgG concentration ≥0,35μg/ml was
considered protective for invasive disease. For the statis-
tical analysis SPSS17 and non-parametric tests were
used. The statistical significance level was set at p<0,05.
Results
One month after vaccination, 96,2% of all 53 children had
protective IgG concentration ≥0,35μg/ml, for each sero-
type. The geometric mean concentration (GMC) of IgG
antibodies after vaccination, the increase in the GMC and
the percentage of children that achieved protective IgG
concentration ≥0,35μg/ml, did not differ for neither of the
serotypes, when compared among our 4 groups (p > 0,05).
Conclusion
The immunogenicity of PCV13, in children with asthma
or recurrent wheeze, is not affected by the use of med-
ium doses of ICS as control therapy, even after extended
periods of time.
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